1 day Ago By Defense World Staff
Allogene Therapeutics, Inc. ( NASDAQ:ALLO – Get Free Report ) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 37,040,000 shares, a decrease of 5.
8% from the October 15th total of 39,320,000 shares. Approximately 26.7% of the company’s shares are short sold.
Based on an average daily volume of 1,980,000 shares, the days-to-cover ratio is currently 18.7 days. Analysts Set New Price Targets A number of equities analysts have issued reports on the company.
HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $11.
00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Truist Financial reiterated a “buy” rating and issued a $14.
00 target price (down from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. Citigroup lifted their price target on shares of Allogene Therapeutics from $7.
00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, Oppenheimer assumed coverage on shares of Allogene Therapeutics in a research report on Thursday, August 8th.
They issued an “outperform” rating and a $11.00 price objective for the company. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock.
According to MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.73. View Our Latest Stock Report on Allogene Therapeutics Institutional Trading of Allogene Therapeutics Allogene Therapeutics Trading Down 1.
4 % ALLO opened at $2.12 on Wednesday. The stock has a market capitalization of $444.
50 million, a P/E ratio of -1.36 and a beta of 0.84.
Allogene Therapeutics has a 12 month low of $2.01 and a 12 month high of $5.78.
The firm’s fifty day simple moving average is $2.73 and its 200 day simple moving average is $2.64.
About Allogene Therapeutics ( Get Free Report ) Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). Featured Articles Five stocks we like better than Allogene Therapeutics Why Special Dividends Can be a Delightful Surprise for Income Investors Super Micro Computer Soars 28%: Is It Really Out of the Woods? EV Stocks and How to Profit from Them Traders Are Flocking Back to Oil: What’s Fueling the Optimism Options Trading – Understanding Strike Price 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
